Welcome to our dedicated page for Federated Hermes SEC filings (Ticker: FHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Federated Hermes, Inc. filings document material events for an asset-management company with liquidity, equity, fixed-income, alternative/private markets and multi-asset businesses. Recent Form 8-K reports include earnings releases, managed-asset disclosures, dividend actions, Class B common-stock consideration, acquisition terms for Federated Hermes FCP Manager, LLC and other capital-structure information.
The filing record also covers governance and executive-officer transitions, shareholder-voting matters, material agreements and legal-risk disclosures tied to investment-management subsidiaries, including Hermes GPE LLP and infrastructure fund matters. These documents connect operating results, platform expansion, leadership structure and risk disclosures to Federated Hermes' public-company reporting.
Saker Anwar Nusseibeh filed a Rule 144 notice to sell 5,800 common shares through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $311,239.60 and an approximate sale date of February 2, 2026.
The filing shows these shares were acquired on March 11, 2022 via restricted stock vesting under a registered plan, with services rendered as consideration. It also discloses prior sales over the past three months of 4,461 and 15,000 common shares, with gross proceeds of $213,447.25 and $728,154.00, respectively.
Federated Hermes, Inc. disclosed that its London-based subsidiary Hermes GPE LLP and Hermes Infrastructure II GP LLP have been sued in the U.K. High Court by Aberdeen City Council as administering authority for the Aberdeen City Council Pension Fund. The case concerns the Fund’s 2019 investment in the Swedish “Ventus Portfolio” of five onshore wind farms.
According to the claimant’s filing, derivative claims on behalf of the Fund’s general partner seek approximately £87 million of alleged diminished value in the Ventus Portfolio (about $120 million), plus other unquantified damages, while direct claims seek about 38.1% of that amount (about $46 million). Federated Hermes and the involved entities deny the allegations, state they believe the claims lack merit, and intend to vigorously defend the case. Based on information currently available, Federated Hermes does not believe the matter will have a material adverse effect on its consolidated financial position, results of operations, or cash flows and has notified its insurers under the applicable policy.
Federated Hermes, Inc. filed a current report to note that it issued an earnings press release for its fourth quarter 2025 results. The company states that this press release, dated January 29, 2026, is attached as Exhibit 99.1 to the report.
The filing also lists an Exhibit 104 cover page interactive data file embedded within the Inline XBRL document. The report is signed on behalf of Federated Hermes, Inc. by Chief Financial Officer Thomas R. Donahue.
Federated Hermes, Inc. has filed a Schedule 13G reporting beneficial ownership of 2,541,863 shares of TTEC Holdings, Inc. common stock, representing 5.24% of the class as of the event date 12/31/2025. Federated Hermes and related reporting persons, including the Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, report sole or shared voting and dispositive power over these shares. They state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of TTEC. The reporting persons also expressly disclaim beneficial ownership of securities held by managed funds.
Federated Hermes, Inc. and related parties have filed a Schedule 13G reporting beneficial ownership of 7,737,166 shares of Ovid Therapeutics Inc. common stock, representing 5.94% of the class as of the 12/31/2025 event date. Federated Hermes and the Voting Shares Irrevocable Trust report sole voting and dispositive power over these shares, while individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue report shared voting and dispositive power over the same 7,737,166 shares.
The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ovid Therapeutics. Federated Hermes, the trust, and the individual filers expressly disclaim beneficial ownership of securities held by the managed funds referenced in the filing.
Federated Hermes, Inc. and related reporting persons filed an amended Schedule 13G/A reporting beneficial ownership of 3,533,250 shares of SCYNEXIS, INC. common stock, representing 8.42% of the class as of 12/31/2025. Federated Hermes has sole voting and dispositive power over these shares, while the Voting Shares Irrevocable Trust reports the same sole voting and dispositive power.
Individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue each report shared voting and shared dispositive power over the same 3,533,250 shares and the same 8.42% stake. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of SCYNEXIS. They also expressly disclaim beneficial ownership of securities held by the managed funds.
Federated Hermes, Inc. and related reporting persons filed an amended Schedule 13G showing beneficial ownership of 1,437,836 shares of MGP Ingredients, Inc. common stock, representing 6.75% of the class as of the stated event date. Federated Hermes and the Voting Shares Irrevocable Trust report sole voting and dispositive power over these shares, while Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue report shared voting and dispositive power over the same amount.
The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MGP Ingredients. They also expressly disclaim that this filing should be construed as an admission that any of them is the beneficial owner of securities held by the managed funds.
Federated Hermes, Inc. filed Amendment No. 3 to a Schedule 13G reporting beneficial ownership of 3,395,771 shares of IDEAYA Biosciences, Inc. common stock, representing 3.87% of the class as of 12/31/2025. The same share amount and percentage are reported for the Voting Shares Irrevocable Trust, and for Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, reflecting shared or sole voting and dispositive powers as disclosed on each cover page.
Federated Hermes, the trust, and the individual filers state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of IDEAYA. They also declare, in accordance with Rule 13d-4, that this filing should not be construed as an admission that any of them is the beneficial owner of securities held by the managed funds, and they expressly disclaim beneficial ownership of those securities. The filing indicates ownership of 5 percent or less of IDEAYA’s common stock.
Federated Hermes, Inc. and related reporting persons filed Amendment No. 3 to a Schedule 13G disclosing their beneficial ownership in Arcturus Therapeutics Holdings Inc. common stock. They report beneficial ownership of 3,303,640 shares of common stock, representing 11.63% of the class as of the event date of 12/31/2025. Federated Hermes has sole voting and dispositive power over these shares, while the Voting Shares Irrevocable Trust and Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue report shared voting and dispositive power over the same amount. The reporting persons state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arcturus, and they expressly disclaim beneficial ownership of securities held by managed funds.
FHI filed a Rule 144 notice covering the planned sale of 5,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $261,192.00. The filing notes that 77,537,867 shares of the issuer’s common stock were outstanding and that the approximate sale date is 12/12/2025 on the NYSE. The shares to be sold were acquired as restricted stock vesting under a registered plan in several grants between 11/18/2024 and 11/18/2025 in exchange for services rendered. During the past three months, Dolores Dudiak sold 999 common shares for gross proceeds of $47,824.53.